Resources
View resources about cytomegalovirus and CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) as well as the locations of our upcoming engagements.
Featured Resources
Kamada's IIS Overview Video
Watch Kamada's Investigator Initiated Study overview video, presented by Winston Ally, PharmD, FAST. Director, US Medical Affairs at Kamada Inc.
Watch Video
UCSF Poster Presentation: Potential Long-Term Benefits of CYTOGAM Use
View the UCSF poster presentation on CMV-related immune mechanisms, CYTOGAM's potential role in immune modulation, and long-term outcomes in lung transplant recipients.
Learn More
Banga 2025 Summary Carrier: Long-Term Outcomes in High-Risk CMV Mismatch Lung Transplant
Download the Banga 2025 summary carrier for a concise overview of 8-year real-world lung transplant data evaluating outcomes in high-risk CMV mismatch recipients managed with a multimodality regimen that included CYTOGAM.
Learn MoreEvents
CYTOGAM offers webinars to healthcare providers and their staff periodically. Additionally, Kamada Inc. participates annually in medical conferences in the United States and internationally. Events will be posted below as they become available.
CMV Stream 2026 is now available on demand
CMV Stream 2026 featured an in-depth discussion on on how the 4th International Consensus Guidelines are being applied in practice, and where challenges still remain. If you missed the live broadcast:
Learn MoreAST Cutting Edge of Transplantation 2027
Join Kamada at CEoT, February 25 – 27, 2027, in Scottsdale, AZ! Kamada is excited to exhibit at the Cutting Edge of Transplantation meeting in Scottsdale again. Join us at our booth and learn how CYTOGAM helps protect solid organ transplant patients. We look forward to seeing you there!
Learn MoreISHLT 47th Annual Meeting & Scientific Sessions
Join Our Team at the ISHLT Annual Meeting, April 14-17, 2027 in Sydney, NSW Australia! At this 47th annual meeting, our team will share recent data and insights into how CYTOGAM may help prevent CMV disease in SOT patients. Join us and learn how CYTOGAM helps protect heart and lung transplant patients. Let’s connect!
Learn MoreAdditional Resources
Videos
CEoT Product Theater 2026: Addressing Ongoing CMV Risk Across Solid Organ Transplant— Tim Pruitt
Watch VideoCEoT Product Theater 2025: Current State of CMV in SOT — Marie Budev
Watch VideoCEoT Product Theater 2025: Supporting Innovation in SOT — Winston Ally
Watch VideoPodcasts
ISHLT Voices Podcast 2026: CMV Management in High-Risk SOT
Listen Now ISHLT Voices Podcast 2025: Emerging CYTOGAM Data in SOT
Listen NowPrint/Downloadable PDFs
Barten 2022 Summary Carrier: CMV Hyperimmunoglobulin Prophylaxis in SOT
Learn More
Germer 2016 Summary carrier: CMV-IGIV vs Standard IVIG: Functional Properties
Learn More